Pharmaceutical omega-3 products are important but will grow more slowly than some expect because of the long timeframe for drug approval, says the chief of the Global Organisation for EPA and DHA Omega-3s (GOED).
Just got off the phone to Ola Snove, the new(ish) CEO of Aker part-owned Norwegian omega-3 specialist Epax. Wanted to know his view on high-end omega-3 prospects that have attracted BASF and DSM to the sector. His word: “Stellar”.
The dietary supplements industry should be encouraged and not threatened by increased scrutiny of its products by the mainstream medical community, because it means they are taking the products – and the questions from their patients – seriously.
The next 5-10 years will present a significant challenge for global business, with a new event promising to help business leaders navigate the ‘biggest period of global change since the industrial revolution’.